ELCC 2014 :专家呼吁重视肺癌患者的性功能障碍

2014-04-21 佚名 dxy

日前,在瑞士日内瓦举行的第四界欧洲肺癌会议(ELCC)上报道的一项研究显示,许多肺癌患者的性表达和性行为遇到了麻烦,然而,这一问题长期以来为研究人员和医生所忽视。研究人员估计,40%到100%的治疗后肺癌患者人群存在性功能障碍问题。研究显示,这一问题会一直存在,而不是随着时间得到自然改善。然而,从目前收集到的大部分资料来看,这一问题与乳腺癌、前列腺癌和妇科癌症相关。而其他癌症如肺癌的这一问题的相关

日前,在瑞士日内瓦举行的第四界欧洲肺癌会议(ELCC)上报道的一项研究显示,许多肺癌患者的性表达和性行为遇到了麻烦,然而,这一问题长期以来为研究人员和医生所忽视。研究人员估计,40%到100%的治疗后肺癌患者人群存在性功能障碍问题。研究显示,这一问题会一直存在,而不是随着时间得到自然改善。然而,从目前收集到的大部分资料来看,这一问题与乳腺癌、前列腺癌和妇科癌症相关。而其他癌症如肺癌的这一问题的相关资料更是少见。

法国NîMES大学医院的STéphane droupy博士称,现在到了医生和科学家对这一问题给予关注的时候了,在以性和癌症为主题的ELCC多学科交互讨论会上,研究者讨论了肺癌治疗后应如何评估性功能和应如何治疗性功能副作用的问题。

研究者称,意识到癌症性问题特别是肺癌性问题的重要性后我们仍有许多需要解决的问题,我们希望ELCC的这一讨论会将有助于促进如何帮助这一患者人群。性功能障碍是肺癌患者人群中的一个较为特殊的问题,因为肺癌的管理经常集中于短期生活质量的改善和姑息治疗;肿瘤学家和患者应在癌症治疗开始前讨论性功能障碍问题,必要时应寻求性健康专业健康护理专家的帮助。

肺癌患者受害尤其严重

肺癌引起的情感和生理后果,以及治疗效应都会影响性功能。举个例子说,当患者了解到自己患有癌症时,他们很容易出现性冷淡。悲伤和抑郁也会减少性欲望。癌症引起的生理变化以及治疗效应如手术、化疗以及放疗的效应都可能对性表达造成负面影响。

研究者称,对于肺癌而言,上述这些问题尤其严重。与其他癌症不同(它们的生存一直以来都有改善的趋势),肺癌的管理往往集中于短期生活质量的改善和姑息治疗上。相比之下,肺癌更重要的是努力增加患者的生存,保护性功能或性功能短期内恢复的难度更大,

荷兰鹿特丹伊拉斯谟医疗中心的放射肿瘤学家和性学家Incrocci博士认为,另一项重要的措施是医患之间开诚布公地讨论患者所面临的问题。医患沟通是关键。
Incrocci博士认为,我们都知道性生活对于生活质量和婚姻关系非常重要,然而,健康护理专家经常忽视癌症患者的性事件。对于患者和健康护理服务者而言,这当然是一件难于处理的事件,但我们仍然要为之付出努力来改善这种情况。

研究者称,在治疗开始时即与患者讨论性生活的问题是迈出的关键性的第一步。这可以帮助医生评估患者以前的性功能障碍和动机,以改善其性生活,并帮助患者了解下一步的治疗措施是怎样的。

当癌症治疗正在进行中时,医生应积极为性生活出现困难的患者提供解决措施,并在癌症管理的同时帮助解决患者的性问题。


研究者认为,治疗措施可能包括药物治疗和性治疗。更重要的是性伙伴的参与,可优化治愈和改善的机率。不管临床情况如何,重建患者的性功能可显著改善癌症患者的情绪状态。对于男性或女性的性别认同感也非常重要。

原始出处

Experts Call for More Awareness of Sexual Dysfunction in Lung Cancer Patients

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081130, encodeId=734e20811300b, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 06 05:14:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034133, encodeId=b96f2034133de, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun May 04 19:14:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034118, encodeId=f6b820341184b, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun Feb 01 09:14:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990528, encodeId=be8b199052828, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jan 16 07:14:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421000, encodeId=bdac14210006c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Apr 23 04:14:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081130, encodeId=734e20811300b, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 06 05:14:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034133, encodeId=b96f2034133de, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun May 04 19:14:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034118, encodeId=f6b820341184b, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun Feb 01 09:14:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990528, encodeId=be8b199052828, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jan 16 07:14:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421000, encodeId=bdac14210006c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Apr 23 04:14:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2014-05-04 chendoc242
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081130, encodeId=734e20811300b, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 06 05:14:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034133, encodeId=b96f2034133de, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun May 04 19:14:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034118, encodeId=f6b820341184b, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun Feb 01 09:14:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990528, encodeId=be8b199052828, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jan 16 07:14:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421000, encodeId=bdac14210006c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Apr 23 04:14:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2015-02-01 chendoc242
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081130, encodeId=734e20811300b, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 06 05:14:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034133, encodeId=b96f2034133de, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun May 04 19:14:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034118, encodeId=f6b820341184b, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun Feb 01 09:14:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990528, encodeId=be8b199052828, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jan 16 07:14:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421000, encodeId=bdac14210006c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Apr 23 04:14:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081130, encodeId=734e20811300b, content=<a href='/topic/show?id=65d02065e3d' target=_blank style='color:#2F92EE;'>#专家呼吁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20657, encryptionId=65d02065e3d, topicName=专家呼吁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Wed Aug 06 05:14:00 CST 2014, time=2014-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034133, encodeId=b96f2034133de, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun May 04 19:14:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034118, encodeId=f6b820341184b, content=<a href='/topic/show?id=ac3066568c' target=_blank style='color:#2F92EE;'>#ELCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6656, encryptionId=ac3066568c, topicName=ELCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sun Feb 01 09:14:00 CST 2015, time=2015-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990528, encodeId=be8b199052828, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Fri Jan 16 07:14:00 CST 2015, time=2015-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421000, encodeId=bdac14210006c, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Apr 23 04:14:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]

相关资讯

PLOS Genetics:中科院上海生科院发表肺癌新成果

2014年4月10日,中科院上海生命科学研究院分子生物学国家重点实验室的惠静毅研究员带领的研究小组,在PLOS Genetics发表题为“The RNA-Binding Protein QKI Suppresses Cancer-Associated Aberrant Splicing”的研究论文,指出RNA结合蛋白QKI可抑制肺癌相关的异常剪接,将QKI确定为肺癌细胞中一种关键的可变剪接调节

PLoS One:非小细胞肺癌检测有新标志物SP70

日前,南京医科大学潘世扬教授团队研究发现了一种针对非小细胞肺癌的特异性蛋白靶标SP70。研究显示,SP70存在于癌细胞的胞膜和胞浆,可促进癌细胞增殖,因此可将它用作肺癌检测诊断的分子靶标,同时也是抗肺癌治疗靶点。该研究相关论文已在《公共科学图书馆·综合》、《中华检验》等杂志上发表。 非小细胞肺癌包括鳞癌、腺癌、大细胞癌等,约占肺癌总数的80%~85%。由于缺少有效的

NEJM:强效抗癌药ceritinib有效之治疗肺癌

诺华研发的Ceritinib是一种ALK抑制剂,体外试验显示,其ALK抑制效果和克里唑蒂尼比较要高出20倍。2014年3月27号NEJM发表了Ceritinib的临床1期研究结果:对克里唑蒂尼耐药的ALK-重排NSCLC患者,服用Ceritinib后所产生的治疗应答率高达56%。 原文摘要 BACKGROUNDNon–small-cell lung cancer (NSCLC) harbo

AACR 2014:肺癌新药MK-3475作用与肿瘤中PD-L1蛋白浓度有关

应用正在研究中的免疫检测点抑制剂MK-3475治疗的非小细胞肺癌患者中,那些肿瘤中PD-L1蛋白浓度较高的患者的预后更好,该I期临床研究结果报告在2014年4月5-9日举行的AACR年会上。该试验的初始数据报道于今年的早些时候,数据显示MK-3475治疗的耐受性较好,可以使以前治疗过的非小细胞肺癌患者达到持久而客观的缓解,尤其是那些在治疗前PD-L1的浓度就很高的肿瘤的患者。最近的结果扩展了这些数

Bioinformatics:中科院发现肺癌新型靶点HKDC1

近日,从中科院昆明动物研究所获悉,在国家自然科学基金委和科技部项目的支持下,该所李功华博士在黄京飞研究员的指导下,建立了新的系统生物学模型,并发现可能是新型的针对肺癌的肿瘤靶标。该研究成果已发表在《生物信息学》上。据悉,肿瘤已是世界人口死亡的首要原因,我国每年因肿瘤死亡的人数超过200万。对此,除了传统的放化疗等方法外,靶向治疗是肿瘤临床的研究热点和发展趋势。该方法通过药物选择性抑制肿瘤细胞特异的

肺癌仍为我国癌症榜“首恶”

作为《2013中国肿瘤登记年报》的主要内容——中国2010年恶性肿瘤发病与死亡等相关数据,因发表在专业期刊《中国肿瘤》2014年第一期上,而提早进入媒体及公众视野。 这一系列最新数据背后究竟蕴含着哪些信息?文章第一作者、全国肿瘤登记中心主任陈万青教授,请其进行解读。 有效登记数据覆盖人数翻番、发病率死亡率均与上年持平 发表在《中国肿瘤》上的文章显示,全国肿瘤登记中心共收集到219个登